Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 16, 2008

Sequenom Bolsters IP Position in Prenatal Testing through Deal with the Chinese University of Hong Kong

  • Sequenom acquired exclusive, worldwide rights to digital PCR and other noninvasive prenatal diagnostic intellectual property from The Chinese University of Hong Kong. The terms of the agreement excludes Hong Kong.

    “This intellectual property is platform-independent and provides Sequenom exclusivity for development and commercialization of noninvasive prenatal tests on any platform,” points out Harry Stylli, Ph.D., president and CEO of Sequenom.

    The license deal includes the use of fetal nucleic acids obtained from a maternal sample and methods of analysis for noninvasive Down (trisomy 21), Edward (trisomy 18), Patau (trisomy 13), and other chromosomal aneuploidy syndrome diagnoses or other autosomal recessive disorders utilizing digital PCR.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »